Abstract:Background and Aims: NLRP3 inflammasome is known to be involved in inflammatory bowel diseases. However, it is controversial whether it is pathogenic or beneficial. This study evaluated the roles of NLRP3 inflammasome in the pathogenesis of inflammatory bowel disease in IL-10(-/-) mice and humans.Methods: NLRP3 inflammasome in colonic mucosa, macrophages, and colonic epithelial cells were analysed by western blotting. The NLRP3 inflammasome components were studied by sucrose density gradient fractionation, chemical cross-linking, and co-immunoprecipitation. The role of NLPR3 inflammasome in the pathogenesis of colitis was extensively evaluated in IL-10(-/-) mice, using a specific NLPR3 inflammasome inhibitor glyburide.Results: NLRP3 inflammasome was upregulated in colonic mucosa of both IL-10(-/-) mice and Crohn's patients. NLRP3 inflammasome activity in IL-10(-/-) mice was elevated prior to colitis onset; it progressively increased as disease worsened and peaked as macroscopic disease emerged. NLRP3 inflammasome was found in both intestinal epithelial cells and colonic macrophages, as a large complex with a molecular weight of >= 360 kDa in size. In the absence of IL-10, NLRP3 inflammasome was spontaneously active and more robustly responsive when activated by LPS and nigericin. Glyburide markedly suppressed NLRP3 inflammasome expression/activation in IL-10(-/-) mice, leading to not only alleviation of ongoing colitis but also prevention/delay of disease onset. Glyburide also effectively inhibited the release of proinflammatory cytokines/chemokines by mucosal explants from Crohn's patients.Conclusions: Abnormal activation of NLRP3 inflammasome plays a major pathogenic role in the development of chronic colitis in IL-10(-/-) mice and humans. Glyburide, an FDA-approved drug, may have great potential in the management of inflammatory bowel diseases.

ADP/P2Y1 Aggravates Inflammatory Bowel Disease Through ERK5-mediated NLRP3 Inflammasome Activation

Activation of P2Y1R impedes intestinal mucosa repair during colitis

Inflammatory-Dependent Bidirectional Effect of Bile Acids on NLRP3 Inflammasome and Its Role in Ameliorating CPT-11-Induced Colitis.

Estrogen receptor α aggravates intestinal inflammation via promoting the activation of NLRP3 inflammasome

Intestinal edema induced by LPS-induced endotoxemia is associated with an inflammasome adaptor ASC

Dextran sodium sulfate potentiates NLRP3 inflammasome activation by modulating the KCa3.1 potassium channel in a mouse model of colitis

Critical role for the NLRP3 inflammasome in colitis and colitis associated colorectal cancer (47.9)

NLRP1 restricts butyrate producing commensals to exacerbate inflammatory bowel disease

Deoxycholic Acid Triggers NLRP3 Inflammasome Activation and Aggravates DSS-Induced Colitis in Mice

NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis

CD1d1 Intrinsic Signaling in Macrophages Controls NLRP3 Inflammasome Expression During Inflammation.

The Pathogenic Role of NLRP3 Inflammasome Activation in Inflammatory Bowel Diseases of Both Mice and Humans.

Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease

The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer

The PGAM5–NEK7 Interaction is a Therapeutic Target for NLRP3 Inflammasome Activation in Colitis

Tyrosine Phosphatase SHP2 Negatively Regulates NLRP3 Inflammasome Activation Via ANT1-dependent Mitochondrial Homeostasis

Biological functions of NLRP3 inflammasome: A therapeutic target in inflammatory bowel disease

Adiponectin and adiponectin receptor 1 overexpression enhance inflammatory bowel disease

Targeting Purinergic Receptor P2RX1 Modulates Intestinal Microbiota and Alleviates Inflammation in Colitis

Does NLRP3 Inflammasome and Aryl Hydrocarbon Receptor Play an Interlinked Role in Bowel Inflammation and Colitis-Associated Colorectal Cancer?

Persistent Activation of the P2X7 Receptor Underlies Chronic Inflammation and Carcinogenic Changes in the Intestine